Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Xin Li
Patients were classified according to the first-line regimen initiated on the index date. Time zero was defined as the date of first administration of pertuzumab plus trastuzumab and chemotherapy or trastuzumab and chemotherapy. Eligibility criteria were assessed using information available on or before time zero. Patients were not required to complete a minimum number of treatment cycles and were followed from treatment initiation regardless of subsequent treatment discontinuation or modification.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
1. Female patients aged 18 years or older on the index date.
2. Histologically or cytologically confirmed breast cancer.
3. HER2-positive disease, defined according to available pathology records as immunohistochemistry (IHC) 3+ or IHC 2+ with positive in situ hybridization.
4. Unresectable locally advanced, recurrent, or metastatic breast cancer on the index date.
5. No prior systemic anticancer therapy for unresectable locally advanced, recurrent, or metastatic breast cancer before the index date.
6. Initiation of first-line treatment with either:
1. pertuzumab plus trastuzumab plus docetaxel; or
2. trastuzumab plus docetaxel between January 1, 2020 and December 31, 2024.
7. Sufficient information available on or before the index date to determine eligibility, treatment assignment, and baseline covariates.
You may not be if
1. Early-stage or resectable breast cancer treated with curative intent on the index date.
2. Prior systemic anticancer therapy for unresectable locally advanced, recurrent, or metastatic breast cancer before the index date.
3. Another active primary malignant tumor on the index date that was expected to materially affect survival.
4. Insufficient or invalid information to determine HER2 status, advanced disease status, index treatment regimen, or index date.
5. Absence of a valid patient identifier required for linkage between the electronic health record database and the mortality registry.
Clareo Health | First-Line Dual Versus Single HER2-Targeted Therapy With Docetaxel for Advanced HER2-Positive Breast Cancer
